Global mRNA Cancer Vaccines Therapeutics Market 2022-2028

December 2022 | 62 pages | ID: G6EBB8AF5FE5EN
Gen Consulting Company

Abstracts

According to latest analysis by Gen Consulting Company, the global mrna cancer vaccines therapeutics market was USD 891 million in 2021 and is expected to reach USD 4,739 million in 2028 and register a CAGR of 27.2% during the forecast period, 2022-2028.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global mrna cancer vaccines therapeutics market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the mrna cancer vaccines therapeutics industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, application, end user, and region. The global market for mrna cancer vaccines therapeutics can be segmented by product: standardization, individualized, infectious disease, infection prevention. The standardization segment captured the largest share of the market in 2021. Mrna cancer vaccines therapeutics market is further segmented by application: cancer, infectious disease, gene editing, protein replacement, others. The infectious disease segment held the largest share of the global mrna cancer vaccines therapeutics market in 2021 and is anticipated to hold its share during the forecast period. Based on end user, the mrna cancer vaccines therapeutics market is segmented into: hospital and clinic, research institute, others. In 2021, the hospital and clinic segment made up the largest share of revenue generated by the mrna cancer vaccines therapeutics market. On the basis of region, the mrna cancer vaccines therapeutics market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Among these, North America was accounted for the highest revenue generator in 2021.

Market Segmentation

By product: standardization, individualized, infectious disease, infection prevention

By application: cancer, infectious disease, gene editing, protein replacement, others

By end user: hospital and clinic, research institute, others

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The global mrna cancer vaccines therapeutics market report offers detailed information on several market vendors, including BioNTech SE, CureVac AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc., Therapeutics Inc., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global mrna cancer vaccines therapeutics market.
• To classify and forecast the global mrna cancer vaccines therapeutics market based on product, application, end user, region.
• To identify drivers and challenges for the global mrna cancer vaccines therapeutics market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global mrna cancer vaccines therapeutics market.
• To identify and analyze the profile of leading players operating in the global mrna cancer vaccines therapeutics market.

Why Choose This Report

• Gain a reliable outlook of the global mrna cancer vaccines therapeutics market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY PRODUCT

Standardization
Individualized
Infectious disease
Infection prevention

PART 6. MARKET BREAKDOWN BY APPLICATION

Cancer
Infectious disease
Gene editing
Protein replacement
Others

PART 7. MARKET BREAKDOWN BY END USER

Hospital and clinic
Research institute
Others

PART 8. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 9. KEY COMPANIES

BioNTech SE
CureVac AG
GlaxoSmithKline plc
Moderna Inc.
Pfizer Inc.
Therapeutics Inc.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER